Navigation Links
Study unveils SINE's potential of re-activating tumor fighting proteins within a cell
Date:11/15/2013

Arnhem, The Netherlands - New study suggests that selective blockade of CRM1-dependent nuclear export represents a completely novel, tumour metastasis-selective approach for the treatment of advanced metastatic prostate cancers.

According to the researchers, the human nuclear export protein chromosomal region maintenance/exportin 1/Xpo1 (CRM1) is the sole exportin mediating transport of many multiple tumor suppressor proteins out of the nucleus. Their study aimed to verify the hypothesis that CRM1 inhibition could be beneficial for the treatment of prostate cancer metastases, which was achieved by testing the effects of the orally available, potent and selective, clinical stage SINE compound KPT 330.

"Although the class of compounds used in our studies SINEs or Selective Inhibitors of Nuclear Export have just recently entered early clinical testing, our results suggest that these agents could be active in patients with androgen-independent prostate cancer," commented study's lead author Dr. Claudio Festuccia, of the University of L'Aquila in Italy.

"Most of the current treatments for prostate cancer work by reducing the levels or blocking the receptors for a set of hormones called androgens. These SINE compounds act through an entirely new mechanism by re-activating a cells own tumor fighting proteins. These tumor fighting proteins, called tumor suppressor proteins, act as a guardian against the development of cancers by detecting damage to a cell's DNA and if DNA damage is found, activating the cell's own suicide program," he explained.

"Since all cancers have a great deal of DNA damage, re-activation of tumour suppressor proteins could cause the cancer to commit suicide. We observed just such an effect with these new SINE drug candidates."

According to the authors, the study also showed that these new SINE drug candidates prevented prostate cancer cells from causing damage to bones.

"The mechanisms of preventing the damage are now being worked out, but it appears that these new SINE drug candidates can suppress a type of bone cell called an osteoclast," said Festuccia.

Osteoclasts are activated by prostate cancer cells to destroy bone, and play an important role in prostate cancer-associated bone disease.


'/>"/>

Contact: Evgenia Starkova
e.starkova@uroweb.org
31-263-890-680
European Association of Urology
Source:Eurekalert

Related medicine news :

1. Study Suggests Vaccine May Help Kids With Brain Cancer
2. Study reveals how cancer drug causes diabetic-like state
3. Coffee Drinking in Pregnancy Wont Lead to Sleepless Baby: Study
4. Lower GI problems plague many with rheumatoid arthritis, Mayo Clinic study finds
5. Veggies Like Broccoli, Cabbage May Help Fight Breast Cancer: Study
6. No Added Cancer Risk From Hip Replacement Materials: Study
7. Reported Decline in U.S. Pneumonia Deaths May Be False: Study
8. Early Study Finds Some Promise for Lung Cancer Vaccine
9. Narcissists Often Ace Job Interviews, Study Finds
10. Sexual objectification of female artists in music videos exists regardless of race, MU study finds
11. Soy may alleviate hot flashes in menopause, large-scale study finds
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/26/2017)... Plano, Texas (PRWEB) , ... May 26, 2017 , ... ... Cord Stimulation System, a powerfully versatile, patient-centric spinal cord stimulation system. The Nuvectra™ Algovita ... , “We are pleased to be the first in Arkansas to introduce the ...
(Date:5/26/2017)... ... May 26, 2017 , ... via ... antimicrobial, mesh back 24/7 task chair specifically designed for clinical areas. Genie Copper ... thrilled to partner with Cupron® to provide customers with a game changing chair ...
(Date:5/26/2017)... Illinois (PRWEB) , ... May 26, 2017 , ... Silver ... The community, which is located on more than four acres of land at 5620 ... independence. , The 103,000 square-foot building includes 125 studio and one-bedroom apartments. Each ...
(Date:5/26/2017)... (PRWEB) , ... May 26, 2017 , ... “THE FLINTHILLS FAMILY-Our Journey to the Cross”: ... FAMILY-Our Journey to the Cross” is the creation of published authors, Bob and Margaret Massey. ... used to say, he is "panther quick and leather tough." His love for others ...
(Date:5/26/2017)... ... ... Water damage to the flooring of several classrooms at The Fort Lee Elementary ... number of critical issues to address before students could return to classes. , First, ... no disruption to class schedules. Second, the project had to comply with New Jersey ...
Breaking Medicine News(10 mins):
(Date:5/22/2017)... Fla. , May 22, 2017  As ... as a whole continue to make the revolutionary ... becomes increasingly important for ensuring positive patient outcomes ... industry stakeholders are shifting focus away from clinical ... and effects of long-term specialty drug therapy utilization ...
(Date:5/18/2017)... 2017  Bayer announced today that the latest research ... at the 53 rd Annual Meeting of the ... 2-6 in Chicago . ... colorectal, liver and thyroid cancers, as well as lymphomas, ... CHRONOS-1 trial of copanlisib in patients with relapsed or ...
(Date:5/15/2017)... , May 15, 2017 Enterin Inc., a privately-held ... and developing novel compounds to treat Parkinson,s disease (PD), has ... is a Phase 1/2a randomized, controlled, multicenter study involving patients ... will enroll 50 patients over a 9-to-12-month period. The first ... 10 patients with PD. Participating sites include Denver ...
Breaking Medicine Technology: